ClinicalTrials.gg
Active, not recruitingNCT05171647SUNMOUpdated Nov 3, 2026Results posted

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Phase 3 interventional study of Mosunetuzumab and Polatuzumab vedotin in Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche. Active, not recruiting at 50 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 3, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche — 1 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · Hoffmann-La Roche.

Enrollment
17th of 49
208 · median 121
Started
2022
with 4 others
Phase 3
11 of 54
none open now
Registered
50th of 54
by date

Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 17th largest by enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2022, is one of 11 in phase 3, and was the 50th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

03

Conditions studied

  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0, 1, or 2
  • CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); transformed follicular lymphoma; follicular lymphoma Grade 3b
  • Have disease to at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
  • Participants who have received only one must be ineligible for stem cell transplant (ASCT)
  • Adequate hepatic, hematologic, and renal function
  • Estimated (CrCl) ≥ 30 mL/min by Cockroft-Gault method or other institutional standard methods
  • Negative test at screening. Participants with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on anti-retroviral therapy for at least 4 weeks, have a of at least 200 microliters, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 9 months after the final dose of polatuzumab vedotin, 12 months after the final dose of rituximab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, and 3 months after the final dose of tocilizumab, as applicable
  • Inability to comply with protocol-mandated activity restrictions
  • Prior treatment with mosunetuzumab or other CD-20-directed bispecific antibodies, or R-GemOx or Gem-Ox
  • Prior treatment with polatuzumab vedotin, with the following exceptions: participants who have a documented response (partial response or complete response) to polatuzumab vedotin and an absence of PD within 12 months from the last dose of polatuzumab vedotin; participants who received up to 2 doses of a polatuzumab vedotin-containing regimen as bridging to CAR-T therapy, and either has a documented disease control (stable disease, partial response, or complete response), or were not assessed for response following treatment with polatuzumab vedotin
  • to any component of the study treatment
  • Grade > 1 peripheral neuropathy
  • Participants with Grade > 1 persistent toxicity related to prior anti-lymphoma treatment (except for alopecia and anorexia, or other toxicities not considered a safety risk for the participant per investigator's judgment)
  • Received anti-lymphoma treatments with monoclonal antibodies, radio-immunoconjugates or antibody-drug conjugates (ADCs) within 4 weeks before the first dose of study treatment
  • Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent ( or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
  • Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
  • within 100 days prior to the first study treatment administration
  • Prior treatment with chimeric antigen receptor (CAR) T cell therapy within 30 days before the first study treatment administration
  • Prior allogenic stem cell transplant (SCT)
  • Have had a solid organ transplantation
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • History of confirmed progressive multifocal leukoencephalopathy
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombination antibody-related fusion proteins)
  • History of other that could affect compliance with the protocol or interpretation of results, with the exception of malignancies with a negligible risk of or death
  • Currently have or have had a past history of central nervous system (CNS) involvement of lymphoma
  • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or in the past 2 years and have no residual neurologic deficits as judged by the investigator, or with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications, are allowed
  • Significant cardiovascular disease such as Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
  • Significant active pulmonary disease
  • Participants with active symptoms of interstitial lung disease and/or pneumonitis, or those with a history of interstitial lung disease and/or pneumonitis within 6 months prior to the first dose of study treatment
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to the first study treatment administration
  • Known or suspected chronic active Epstein-Barr virus (EBV) infection
  • Recent major surgery within 4 weeks prior to the first study treatment administration
  • Positive test results for chronic infection
  • Acute or chronic virus (HCV) infection
  • Have been administered a live, attenuated vaccine within 4 weeks before the first dose of study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
  • Participants who have positive SARS-CoV-2 test within 7 days prior to enrollment (rapid antigen test result is acceptable)
  • History of disease
  • Received investigational therapy, whether or not intended for lymphoma treatment, within 7 days prior to initiation of study treatment
  • history of liver disease, including viral or other hepatitis, or cirrhosis
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    M+P (Arm A)

    Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.

    Drug: Mosunetuzumab · Drug: Polatuzumab vedotin · Drug: Tocilizumab

  • Active comparator
    R-GemOx (Arm B)

    Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.

    Drug: Rituximab · Drug: Gemcitabine · Drug: Oxaliplatin

Interventions

  • Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).

  • Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).

  • Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.

  • Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

  • Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

  • Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)

    ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.

    Time frame: Up to approximately 23.8 months

  2. Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

    PFS was defined as the time from randomization to first occurrence of disease progression (PD) or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.

    Time frame: Up to 32 months

Secondary outcomes

  1. ORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population

    ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.

    Time frame: Up to 32 months

  2. ORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population

    ORR was defined as the percentage of participants with CR or PR, as determined by the investigator, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  3. Duration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

    DoR was defined as the time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.

    Time frame: Up to 32 months

  4. DoR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

    DoR=time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per investigator, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  5. Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS.

    Time frame: Up to 32 months

  6. PFS as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

    PFS was defined as the time from randomization to first occurrence of PD or death from any cause, whichever occurred first, as determined by the investigator, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  7. Complete Response Rate (CRR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

    CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the IRF, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  8. CRR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

    CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the investigator, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  9. Duration of Complete Response (DOCR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

    DOCR was defined as the time from first occurrence of a documented CR to PD, per IRF, per Lugano Response Criteria.

    Time frame: Up to 32 months

  10. DOCR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

    DOCR=time from first occurrence of documented CR to PD, as determined by the investigator, per Lugano Response Criteria.

    Time frame: Up to approximately 58 months

  11. Time to Deterioration in Physical Functioning (PF), as Measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire-Core 30 (EORTC QLQ-C30)

    Time to deterioration in PF was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning scales were scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a functioning scale indicated high/healthy level of functioning.

    Time frame: Up to approximately 58 months

  12. Time to Deterioration in Fatigue Scale, as Measured by the EORTC QLQ-C30

    Time to deterioration in fatigue was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Fatigue scale was scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a fatigue scale indicated a high level of symptom severity.

    Time frame: Up to approximately 58 months

  13. Time to Deterioration in Lymphoma Symptoms, as Measured by Functional Assessment of Cancer Therapy- Lymphoma Questionnaire (FACT- Lym LymS)

    Time to deterioration in lymphoma-specific symptoms was defined as the time from randomization to the first documentation of a 3-point or more decrease, from baseline. FACT-Lym is a cancer-specific scale used to assess health-related QoL aspects relevant to participants with lymphoma. The full measure consists of the FACT-G physical, social/family, emotional, and functional well-being scales (27 items), as well as lymphoma-specific symptoms subscale (LymS). The FACT-Lym Lyms consists of 15 items scored from 0-4, where 0="Not at all" and 4="very much". Scale score ranges from 0 to 60, where a high score indicated a better QoL.

    Time frame: Up to approximately 58 months

  14. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

    Time frame: Up to approximately 58 months

  15. Number of Participants With Cytokine Release Syndrome (CRS) With Severity Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale

    CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.

    Time frame: Up to approximately 58 months

  16. Number of Participants With Dose Interruptions, Dose Reductions and Study Treatment Discontinuation Due to AEs

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention. Participants who had dose interruptions or modifications or who discontinued study treatment due to AEs will be reported here.

    Time frame: Up to approximately 58 months

  17. Dose Intensity of Mosunetuzumab

    Time frame: Up to approximately 58 months

  18. Change From Baseline in Peripheral Neuropathy (PN), as Measured by the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)

    The FACT/GOG-Ntx is an 11-item patient-reported outcome that measures polatuzumab vedotin-induced PN. The scale contains 4 subscales to assess sensory neuropathy (4 items), hearing neuropathy (2 items), motor neuropathy (3 items), and dysfunction associated with neuropathy (2 items), which can be summed to create a total score. Each item is scored on a 5-point response scale that ranges from 0=not at all to 4=very much. The possible range for the scores is 0-44, with higher scores indicating more extreme neuropathy.

    Time frame: Up to approximately 58 months

07

Results

Posted Mar 6, 2026

Participant flow

A total of 208 participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL), and follicular lymphoma (FL) Grade 3B (FL3B), ineligible for autologous stem cell transplant (ASCT), took part in the study at 54 investigative sites across 13 countries. The study is still ongoing.

Participant flow — Overall Study
MilestoneArm A: Mosun-PolaArm B: R-GemOx
Started13870
Safety-evaluable (se) population13564
Completed00
Not completed13870
Withdrew: Death6432
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject811
Withdrew: Physician decision10
Withdrew: Reason not specified01
Withdrew: Ongoing in study6425

Outcome measures

SecondaryORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population

ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.

Time frame:
Up to 32 months

Results for this outcome have not been posted.

SecondaryORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population

ORR was defined as the percentage of participants with CR or PR, as determined by the investigator, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

DoR was defined as the time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.

Time frame:
Up to 32 months

Results for this outcome have not been posted.

SecondaryDoR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

DoR=time from first occurrence of documented PET-CT and/or CT-based objective response (OR) (CR/PR) to PD, or death from any cause, whichever occurred first, per investigator, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS.

Time frame:
Up to 32 months

Results for this outcome have not been posted.

SecondaryPFS as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

PFS was defined as the time from randomization to first occurrence of PD or death from any cause, whichever occurred first, as determined by the investigator, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

PrimaryObjective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)

ORR was defined as the percentage of participants with complete response (CR)/partial response (PR), per IRF, per Lugano Response Criteria. Percentages have been rounded off.

Time frame:
Up to approximately 23.8 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)
percentage of participantsArm A: Mosun-PolaArm B: R-GemOx
Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)69.7 (60.65 to 77.83)44.1 (31.16 to 57.60)
Statistical analysis
  • Arm A: Mosun-Pola vs Arm B: R-GemOx · Cochran-Mantel-Haenszel · p = 0.0008 · Difference in overall response rates: 25.68 · 95% CI 9.60 to 41.76
PrimaryProgression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

PFS was defined as the time from randomization to first occurrence of disease progression (PD) or death from any cause, whichever occurred first, per IRF, per Lugano Response Criteria.

Time frame:
Up to 32 months
Reported as:
Median · months
Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans
monthsArm A: Mosun-PolaArm B: R-GemOx
Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans11.5 (5.6 to 17.6)3.8 (2.9 to 4.1)
Statistical analysis
  • Arm A: Mosun-Pola vs Arm B: R-GemOx · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.41 · 95% CI 0.28 to 0.61
SecondaryComplete Response Rate (CRR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the IRF, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryCRR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

CRR was defined as the percentage of participants in whom CR was observed at any time during the study, based on PET-CT and/or CT scans, as determined by the investigator, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryDuration of Complete Response (DOCR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

DOCR was defined as the time from first occurrence of a documented CR to PD, per IRF, per Lugano Response Criteria.

Time frame:
Up to 32 months

Results for this outcome have not been posted.

SecondaryDOCR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans

DOCR=time from first occurrence of documented CR to PD, as determined by the investigator, per Lugano Response Criteria.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryTime to Deterioration in Physical Functioning (PF), as Measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire-Core 30 (EORTC QLQ-C30)

Time to deterioration in PF was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning scales were scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a functioning scale indicated high/healthy level of functioning.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryTime to Deterioration in Fatigue Scale, as Measured by the EORTC QLQ-C30

Time to deterioration in fatigue was defined as time from randomization to the first documentation of 10-point or more decrease, from baseline. EORTC QLQ-C30 is cancer-specific instrument consisting of 30 questions to evaluate 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea, vomiting, \& pain), global health status (GHS)/quality of life (QoL), \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Fatigue scale was scored on a 4-point scale, ranging from 1=Not at all to 4=Very much. All EORTC scales \& single-item measures were linearly transformed to a score range of 0-100. High score for a fatigue scale indicated a high level of symptom severity.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryTime to Deterioration in Lymphoma Symptoms, as Measured by Functional Assessment of Cancer Therapy- Lymphoma Questionnaire (FACT- Lym LymS)

Time to deterioration in lymphoma-specific symptoms was defined as the time from randomization to the first documentation of a 3-point or more decrease, from baseline. FACT-Lym is a cancer-specific scale used to assess health-related QoL aspects relevant to participants with lymphoma. The full measure consists of the FACT-G physical, social/family, emotional, and functional well-being scales (27 items), as well as lymphoma-specific symptoms subscale (LymS). The FACT-Lym Lyms consists of 15 items scored from 0-4, where 0="Not at all" and 4="very much". Scale score ranges from 0 to 60, where a high score indicated a better QoL.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Cytokine Release Syndrome (CRS) With Severity Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale

CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Dose Interruptions, Dose Reductions and Study Treatment Discontinuation Due to AEs

An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study intervention. Participants who had dose interruptions or modifications or who discontinued study treatment due to AEs will be reported here.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryDose Intensity of Mosunetuzumab
Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Peripheral Neuropathy (PN), as Measured by the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)

The FACT/GOG-Ntx is an 11-item patient-reported outcome that measures polatuzumab vedotin-induced PN. The scale contains 4 subscales to assess sensory neuropathy (4 items), hearing neuropathy (2 items), motor neuropathy (3 items), and dysfunction associated with neuropathy (2 items), which can be summed to create a total score. Each item is scored on a 5-point response scale that ranges from 0=not at all to 4=very much. The possible range for the scores is 0-44, with higher scores indicating more extreme neuropathy.

Time frame:
Up to approximately 58 months

Results for this outcome have not been posted.

Adverse events

Collected over From initiation of study drug up to approximately 33.7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Mosun-Pola66/135 (48.9%)45/135 (33.3%)129/135 (95.6%)
Arm B: R-GemOx35/64 (54.7%)16/64 (25%)60/64 (93.8%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventArm A: Mosun-PolaArm B: R-GemOx
PneumoniaInfections and infestations2/1354/64
Cytokine release syndromeImmune system disorders7/1350/64
COVID-19Infections and infestations6/1351/64
COVID-19 pneumoniaInfections and infestations5/1351/64
SepsisInfections and infestations1/1352/64
HyponatraemiaMetabolism and nutrition disorders1/1352/64
Urinary tract infectionInfections and infestations4/1350/64
Febrile neutropeniaBlood and lymphatic system disorders3/1350/64
PneumonitisRespiratory, thoracic and mediastinal disorders3/1350/64
AnaemiaBlood and lymphatic system disorders0/1351/64
Most frequent other events
Showing 10 of 49
Most frequent other events
EventArm A: Mosun-PolaArm B: R-GemOx
Injection site reactionGeneral disorders71/1350/64
AnaemiaBlood and lymphatic system disorders41/13527/64
ThrombocytopeniaBlood and lymphatic system disorders5/13522/64
Platelet count decreasedInvestigations7/13521/64
NeutropeniaBlood and lymphatic system disorders44/13518/64
Neutrophil count decreasedInvestigations19/13518/64
NauseaGastrointestinal disorders17/13517/64
DiarrhoeaGastrointestinal disorders14/13515/64
Cytokine release syndromeImmune system disorders29/1350/64
Infusion related reactionInjury, poisoning and procedural complications8/13513/64

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants, with participants grouped according to their assigned treatment.

Age, Continuous
Age, Continuous(years)Arm A: Mosun-PolaArm B: R-GemOxTotal
Mean60.2 ± 14.361.7 ± 12.760.7 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Mosun-PolaArm B: R-GemOxTotal
Female622587
Male7645121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Mosun-PolaArm B: R-GemOxTotal
Hispanic or Latino472269
Not Hispanic or Latino8848136
Unknown or Not Reported303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Mosun-PolaArm B: R-GemOxTotal
American Indian or Alaska Native9514
Asian562682
Native Hawaiian or Other Pacific Islander101
Black or African American415
White613899
More than one race202
Unknown or Not Reported505
08

Study locations

50 sites
09

References and documents

Publications

  • Kim WS, Zhang H, Maruyama D, Pavlovsky A, Rego EM, Hong H, Goto H, Fesler M, Goodgame B, Li Z, Olszewski AJ, Ashby J, Yin S, Ead WS, Janousek M, Pham S, Batlevi CL, Wei MC, Westin J, Budde LE. Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial. Clin Lymphoma Myeloma Leuk. 2026 Oct 12:S2152-2650(26)04002-4. doi: 10.1016/j.clml.2026.10.009. Online ahead of print. PubMed 42971868 ↗
  • Maruyama D, Goto H, Kumode T, Aizawa K, Fukuhara N, Westin JR, Kim WS, Mori C, Imaizumi T, Kato K. Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. Int J Clin Oncol. 2026 Aug;31(8):1547-1556. doi: 10.1007/s10147-026-03042-x. Epub 2026 Jun 15. PubMed 42298056 ↗
  • Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, Olszewski AJ, Naik S, Ghosh N, Pham S, Wei MC, Batlevi C, To I, Ead W, Makadia S, Penuel E, Jing J, Budde LE. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. Am J Hematol. 2026 Sep;101(9):2177-2189. doi: 10.1002/ajh.70403. Epub 2026 Jun 12. PubMed 42283231 ↗
  • Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Dec 20;43(36):3799-3811. doi: 10.1200/JCO-25-01957. Epub 2025 Oct 2. PubMed 41037766 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Feb 2025, 33 months.

Results were first posted in Mar 2026, 1 year after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 33 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 29, 2021
StartActual
Apr 25, 2022
Primary completionActual
Feb 17, 2025
CompletionEst.
Feb 28, 2027
Results first posted
Mar 6, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Hamilton Health Sciences - Juravinski Cancer Centre · Hamilton, Canada
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site removed
    Show 1 removed
    • Hamilton Health Sciences - Juravinski Cancer Centre · Hamilton, Canada
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05171647
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 29, 2021
Start date
Apr 25, 2022
Primary completion
Feb 17, 2025
Completion
Feb 28, 2027 (estimated)
Results posted
Mar 6, 2026
Last update
Nov 3, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin

Start the discussion